share_log

HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $18

HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $18

HC Wainwright & Co.维持对oncternal therapeutics的买入评级,将目标价格下调至18美元。
Benzinga ·  2024/08/12 17:52  · 评级/大行评级

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and lowers the price target from $19 to $18.

HC Wainwright & Co. 分析师拉古拉姆·塞尔瓦拉朱维持Oncternal Therapeutics(纳斯达克股票代码:ONCT)的买入并将目标股价从19美元下调至18美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发